Treatment with telbivudine positively regulates antiviral immune profiles in chinese patients with chronic hepatitis B

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1304-1311

  Ma, Liang ^a   Cai, Yan Jun ^a   Yu, Lei ^b   Feng, Jun Yan ^a   Wang, Juan ^a   Li, Cong ^a   Niu, Jun Qi ^a   Jiang, Yan Fang ^a  

^a JILIN UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD56 ANTIGEN; GAMMA INTERFERON; IBUPROFEN; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR; METOCLOPRAMIDE; TELBIVUDINE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; GENOTYPE; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNOREGULATION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROCONVERSION; SEROLOGY; T LYMPHOCYTE; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ADULT; ALANINE TRANSAMINASE; ANTIGENS, CD; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; THYMIDINE;

EID: 84874089203     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02181-12     Document Type: Article

References (47)

1. Hoofnagle JH, Dusheiko GM, Seef LB, Jones EA, Waggoner JG, Baies ZB. 1981. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann. Intern. Med. 94:744 -748.
2. Iloeje UH, Yang HI, Su J, Jen CL, Chen CJ. 2006. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678-686.
3. Chen CJ, Yang HI, Su J, Jen SL, Lu SN, Huang GT, Lloeie UH. 2006. Risk of hepato-cellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73.
4. Rehermann B, Nascimbeni M. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol. 5:215-229.
5. + T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77:68 -76.
6. Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti G, Missale G, Pilli M, Urbani S. 2003. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 39: 595- 605.
7. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J. 2000. The role of virus-specific CD8 cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191:1269 -1280.
8. Mosmann TR, Sad S. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology 17:138 -146.
9. O'Garra A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8:275-283.
10. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. 2009. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)17, T(H)1 and T(H)2 cells. Nat. Immunol. 10:864-887.
11. Huang CF, Lin SS, Ho YC, Chen FL, Yang CC. 2006. The immune response induced by hepatitis B virus principal antigens. Cell. Mol. Immunol. 3:97-106.
12. Sakaguchi S. 2004. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531-562.
13. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao JM, Zhang B, Shi M, Ding X, Tang Z, Fu YX, Wang FS. 2006. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 177:739 -747.
14. Manigold T, Racanelli V. 2007. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect. Dis. 7:804-813.
15. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. 2007. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 361:141-148.
16. Franzese O, Kennedy PT, Gehring AJ. 2005. Modulation of the CD8+ T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J. Virol. 79:3322-3328.
17. Bonorino P, Ramzan M, Camous X, Dufeu-Duchesne T, Thelu MA, Sturm N, Dariz A, Guillermet C, Pemollet M, Zarski JP, Marche PN, Leroy V. 2009. Fine characterization of intra-hepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J. Hepatol. 30:1010- 1016.
18. Tangye SG, Cherwinski H, Lanier LL, Phillips JH. 2000. 2B4-mediated activation of human natural killer cells. Mol. Immunol. 37:493-501.
19. Sandusky MM, Messmer B, Watzl C. 2006. Regulation of 2B4 (CD244)- mediated NK cell activation by ligand-induced receptor modulation. Eur. J. Immunol. 12:3268 -3276.
20. Jiang Y, Li W, Yu L, Liu J, Xin G, Yan H, Sun P, Zhang H, Xu D, Niu J. 2011. Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies. Cell. Mol. Immunol. 8:75- 82.
21. Jiang YF, Ma ZH, Xin GJ, Yan HQ, Li WY, Xu HN, Hao CH, Niu JQ, Zhao PW. 2010. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm. 2010:143026. doi:10.1155/2010/143026.
22. Liaw YF, Lau GK, Kao JH, Gane E. 2010. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig. Dis. Sci. 55:2727-2734.
23. Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hemandez B, Juodawlkis A. 2010. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir. Chem. Chemother. 12:119 -129.
24. Rasenack J, Poynard T, Lai CL, Gane E, Brown NA, Healthcote J. 2007. Efficacy of telbivudine vs lamivudine at 2 years in patients with HBeAgpositive chronic hepatitis B who are eligible for treatment based on guidelines. J. Hepatol. 46(Suppl 1):S195.
25. Jia JD, Hou JL, Yin YK. 2007. Two-year results of a phase III comparative trial of telbivudine vs lamivudine in Chinese patients. J. Hepatol. 46(Suppl 1):S189.
26. Ji-Yuan Zhang JY, Song CH, Shi F, Zhang Z, Fu JL, Wang FS. 2010. Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One 5:e13869. doi:10.1371/journal.pone.0013869.
27. Yim HJ, Lok AS. 2006. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 43: S173-S181.
28. Duramad P, McMahon CW, Hubbard A. 2004. Flow cytometric detection of intracellular Th1/Th2 cytokines using whole blood: validation of immunologic biomarker for use in epidemiologic studies. Cancer Epidemiol. Biomarkers Prev. 13:1452-1458.
29. Standring DN, Bridges EG, Placidi L. 2010. Antiviral beta-Lnucleosides specific for hepatitis B virus infection. Antivir. Chem. Chemother. 1:119 -129.
30. Palumbo E. 2008. Telbivudine for chronic hepatitis B. A review. Anti Infect. Agents Med. Chem. 7:245-248.
31. Zhu XF, Lu LX, Wang Y, Xu KW, Li DJ, Zhu X, Liu C, Wang JR, Tang H, Wang LC. 2011. Effect and predictive elements for 52 weeks' telbivudine treatment on naive HBeAg positive chronic hepatitis B. Hepat. Mon. 11:980 -985.
32. Crotta S, Stilla A, Wack A, Andrea A, Nuti S, Doro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abrignani S, Vailiante NM. 2002. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 195:35- 41.
33. Tseng CT, Klimpel GR. 2002. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195:43- 49.
34. Lanier LL. 2005. NK cell recognition. Annu. Rev. Immunol. 23:225-274.
35. Orange JS, Fassett MS, Koopman LA, Boyson JE. 2002. Viral evasion of natural killer cells. Nat. Immunol. 3:1006 -1012.
36. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. 2006. CD127 expression inversely correlates with Foxp3 and suppressive function of human CD4+ Treg cells. J. Exp. Med. 203:1701-1711.
37. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kusters JG, Janseen HL. 2005. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41:771-778.
38. + regulatory T cells modulate immune tolerance and acute exacerbation on the natural history of chronic hepatitis B virus infection. J. Biomed. Sci. 14: 43-57.
39. Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. 2008. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol. Immunol. 45:963-970.
40. Fourel I, Cullen JM, Saputelli J, Aldrich CE, Schaffer P, Averett DR, Pugh J, Mason WS. 1994. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J. Virol. 68:8321- 8330.
41. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825- 829.
42. Cooksley H, Chokshi S, Maayan Y, Wedemeyer H, Andreone P, Gilson R, Warnes T, Paganin S, Zoulim F, Frederick D, Neumann AU, Brosgart CL, Naoumov NV. 2008. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD41 T-cell reactivity. Antimicrob. Agents Chemother. 52:312-320.
43. McClary H, Koch R, Chisari FV, Guidotti LG. 2000. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J. Virol. 74:2255-2264.
44. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D. 1996. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 334: 1422-1427.
45. Kakumu S, Fukatsu A, Shinagawa T. 1992. Localization of intrahepatic interleukin 6 in patients with acute and chronic liver disease. Chin. Pathol. 45:408.
46. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. 1998. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102:968 -975.
47. Lok AS, McMahon BJ. 2001. Chronic hepatitis B. Hepatology 34:1225- 1241.